Debang shares adjusted painfully, deducting the first loss in 10 years. Cui Weixing's share price rose 19% before his retreat
Stock speculation depends on the Research Report of Jinqilin analyst. It is authoritative, professional, timely and comprehensive to help you tap the potential theme opportunities! In the fierce market competition, Cui Weixing, 52, seems to have lost. On the evening of March 6, the logistics enterprise Debang Co., Ltd. (603056. SH) announced that there was significant uncertainty about whether the major matters related to the change of ownership structure being planned by the controlling shar...
Debang shares adjusted painfully, deducting the first loss in 10 years. Cui Weixing's share price rose 19% before his retreat
Stock speculation depends on the Research Report of Jinqilin analyst. It is authoritative, professional, timely and comprehensive to help you tap the potential theme opportunities! In the fierce market competition, Cui Weixing, 52, seems to have lost. On the evening of March 6, the logistics enterprise Debang Co., Ltd. (603056. SH) announced that there was significant uncertainty about whether the major matters related to the change of ownership structure being planned by the controlling shar...
Huaniche biology completed nearly 300 million yuan of round B financing, leading investment such as Gaorong capital
DoNews news on March 3 (Zhai Jiru) it is reported that huaniche biology announced the completion of nearly 300 million yuan of round B financing, which was jointly led by Gaorong capital, CICC Qide fund under CICC capital and CICC Qiyuan national emerging industry venture capital guidance fund, and followed by new and old shareholders such as China Kexing and Sinopharm Zhongsheng. It is reported that this round of financing will be used for R & D and upgrading, expanding the production capaci...
Huaniche biology completed nearly 300 million yuan of round B financing, leading investment such as Gaorong capital
DoNews news on March 3 (Zhai Jiru) it is reported that huaniche biology announced the completion of nearly 300 million yuan of round B financing, which was jointly led by Gaorong capital, CICC Qide fund under CICC capital and CICC Qiyuan national emerging industry venture capital guidance fund, and followed by new and old shareholders such as China Kexing and Sinopharm Zhongsheng. It is reported that this round of financing will be used for R & D and upgrading, expanding the production capaci...
